Experienced in Undifferentiated Connective Tissue Disease (UCTD)

Dr. Elizabeth R. Volkmann

Rheumatology
The Regents Of The University Of California
141 Triunfo Canyon Rd, 
Westlake Village, CA 
Offers Telehealth
17 Years of Experience
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
The Regents Of The University Of California
141 Triunfo Canyon Rd, 
Westlake Village, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Volkmann is a Rheumatologist in Westlake Village, California. Dr. Volkmann has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleroma, and Sarcoidosis.

Her clinical research consists of co-authoring 135 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2008
Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
141 Triunfo Canyon Rd, Westlake Village, CA 91361
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Ucla Medical Plz, Suite 165 34, Los Angeles, CA 90095
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200: A Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Diffuse Cutaneous Systemic Sclerosis
A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200: A Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drug: AVID200 TGFBeta Inhibitor
Study Phase: Phase 1
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment Status: Terminated
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drug: Belumosudil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
View 4 Less Clinical Trials

135 Total Publications

Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study.
Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multiperspective Qualitative Study.
Journal: CHEST pulmonary
Published: September 08, 2025
Similar Doctors
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Jeremy Anuntiyo
Rheumatology
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Jeremy Anuntiyo
Rheumatology
1360 W 6th St, Suite 310, 
San Pedro, CA 
 (41.9 miles away)
562-529-7772
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeremy Anuntiyo is a Rheumatologist in San Pedro, California. Dr. Anuntiyo is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Undifferentiated Connective Tissue Disease (UCTD), Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Sjogren Syndrome.

Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Orrin M. Troum
Rheumatology
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Orrin M. Troum
Rheumatology
2336 Santa Monica Boulevard, Suite 207, 
Santa Monica, CA 
 (22.3 miles away)
310-449-1999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Orrin Troum is a Rheumatologist in Santa Monica, California. Dr. Troum is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Rheumatoid Arthritis (RA), Undifferentiated Connective Tissue Disease (UCTD), Osteoporosis, and Postmenopausal Osteoporosis. Dr. Troum is currently accepting new patients.

Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ginder M. Marshall
Rheumatology
Distinguished in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Ginder M. Marshall
Rheumatology
655 E Queen St, 
Inglewood, CA 
 (31.2 miles away)
310-673-8372
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ginder Marshall is a Rheumatologist in Inglewood, California. Dr. Marshall is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Undifferentiated Connective Tissue Disease (UCTD), Synovitis, Tenosynovitis, and Antisynthetase Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Volkmann's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile